drugset / Trial / NCT00250575

A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia

NCT00250575

Phase 3 Completed 43 enrolled Novartis
NaSingle-groupOpen-labelTreatment

Summary

Clozapine is an antipsychotic. This 24-week study will evaluate the safety and efficacy of clozapine in patients with treatment-resistant schizophrenia. This study is not recruiting in the United States.

Timeline

Start
2005-11
Primary completion
2009-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Clozapine Other / unclassified

Indications